[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![whispertickers Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1937935302200373248.png) WhisperTick [@whispertickers](/creator/twitter/whispertickers) on x XXX followers
Created: 2025-07-27 08:16:04 UTC

You call this progress? $TMDX upended organ transplants, doubled revenues in a year, and still lost a quarter of its value since June.

Q1 2025: Revenue $143.5m, EPS $XXXX. Both comfortably ahead of estimates. Guidance raised. Yet shares trade at $108, while DCF says fair value is closer to $XXX. More detail buried here:

• XXXXX transplants last year. Ambitious XXXXXX in sight for 2028
• Margins rising, sector sentiment not so much
• Competition and scale headaches loom

Decent case for a medtech re-rate if the next set of numbers (out XX July) hold up. Otherwise, just another growth story staring down a skeptical market.

Still confident?


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949383270551929181/c:line.svg)

**Related Topics**
[stocks](/topic/stocks)
[$1435m](/topic/$1435m)
[doubled](/topic/doubled)
[$tmdx](/topic/$tmdx)

[Post Link](https://x.com/whispertickers/status/1949383270551929181)